FRANKLIN LAKES, N.J., July 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving ...

Becton Dickinson (BDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a ...

Core Viewpoint - Investors in the Medical - Dental Supplies sector should consider Becton Dickinson (BDX) and Merit Medical (MMSI) for potential value investment opportunities [1] Group 1: Zacks Rank and Earnings Outlook - Becton Dickinson has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Merit Medical has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank system favors stocks with positive revisions to earnings estimates, suggesting BDX has an improving earnings outlook [3] Group 2: Valuation Metrics - BDX has a forward P/E ratio of 17.73, significantly lower than MMSI's forward P/E of 25.96 [5] - BDX's PEG ratio is 2.02, while MMSI's PEG ratio is higher at 2.41, indicating BDX may be more favorably valued considering expected earnings growth [5] - BDX's P/B ratio stands at 2.60, compared to MMSI's P/B of 4.02, further suggesting BDX is undervalued relative to its book value [6] Group 3: Value Grades - BDX has a Value grade of B, while MMSI has a Value grade of C, indicating that BDX is perceived as a better value investment [7]

More on the News The company has advised customers to prioritize vial use based on clinical needs, following guidelines from the Infectious Disease Society of America and the World Health Organization. While BD does not anticipate a significant financial impact from this issue, it is fully focused on restoring the supply of blood culture vials to normal levels. Price Performance Image Source: Zacks Investment Research Quest Diagnostics, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term g ...

According to the U.S. Census Bureau, the "U.S. population age 65 and over grew nearly five times faster than the total population over the 100 years from 1920 to 2020." Not only that, the older population reached 55.8 million, representing 16.8% of the nation in 2020. Thanks to the post-World War II baby boom, a mass of humanity entered the frame. Brookdale Senior Living (BKD) Still, prospective investors will require some patience. In the past four quarters, the company incurred a loss per share of 19 cent ...

Core Insights - BD (Becton, Dickinson and Company) is addressing a supply issue related to its BACTEC™ blood culture vials, which is not expected to have a material financial impact on the company [1][2][4] - The company is taking measures to mitigate the impact on patient care by manually allocating blood culture vials and advising customers to prioritize usage based on clinical needs [2][4] Company Overview - BD is a leading global medical technology company with a commitment to improving medical discovery, diagnostics, and care delivery [1][3] - The company employs approximately 70,000 individuals and operates in nearly every country, collaborating with organizations to tackle global health challenges [1] Supply Chain Management - The company is experiencing reduced availability of blood culture vials from its supplier and is implementing various strategies to address this issue, including providing manufacturing expertise to the supplier and modifying production schedules [4] - BD is also collaborating with the U.S. Food and Drug Administration to explore options for mitigating supply delays [4] Communication with Stakeholders - BD has communicated with healthcare providers regarding the supply situation and is actively working to ensure that the majority of global demand is met [2][4] - The company has set up a dedicated website for updates on the BACTEC™ blood culture vials supply [5]

FRANKLIN LAKES, N.J., July 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has surpassed its Scope 1 and 2 science-based greenhouse gas (GHG) emissions reduction targets for FY 2023 by 5 percentage points and received approval for near and long-term science-based emissions reduction targets from the Science Based Target initiative (SBTi)[1]. This furthers the company's progress toward its goal to reach net zero GHG emis ...

Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. The tool is intended to help scientists better understand how the molecular machinery within a cell function and how it regulates changes in a cell that can lead to cancer and other diseases. Single-cell studies of various areas of health and disease are currently being conducted by researchers worldwide uti ...

BD Rhapsody™ ATAC-Seq Assay Helps Researchers Understand DNA Regulation and Enable Advancements in Precision Medicine Commercially available globally today, the BD Rhapsody™ ATAC-Seq Assay, BD Rhapsody™ TCR/BCR Next Multiomic Assay and BD Rhapsody™ Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody™ Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell multiomic research. Commercially available globally today, the BD Rhapsody™ ATAC-Seq Assay, BD R ...

BD will issue a detailed announcement prior to each quarter's webcast, confirming the date and time of the earnings news release and webcast for that quarter. Third Quarter Fiscal 2024 —Thursday, August 1, 2024 at 8:00 a.m. (ET) Fourth Quarter Fiscal 2024 — Thursday, November 7, 2024 at 8:00 a.m. (ET) Contacts: FRANKLIN LAKES, N.J., June 20, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to disc ...